We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Image-Guided Breast Biopsy Predicts Residual Cancer

By MedImaging International staff writers
Posted on 21 Oct 2020
Image: Image-guided breast biopsy helps detect lingering cancer cells (Photo courtesy of SciencePhoto)
Image: Image-guided breast biopsy helps detect lingering cancer cells (Photo courtesy of SciencePhoto)
Image-guided breast biopsy following neoadjuvant chemotherapy (NACT) can be used to assess the presence of residual cancer, according to a new study.

The study, by researchers at the Royal Marsden NHS Foundation Trust (London, United Kingdom), the University of Texas MD Anderson Cancer Center (MD Anderson; Houston, USA), and Seoul National University Hospital (SNUH; South Korea) set out to assess the accuracy of post-NACT image-guided biopsy to predict residual cancer in the breast. Of 166 women involved, 143 had image-guided vacuum-assisted biopsy (VAB), and 23 had core-cut biopsies.

Ultrasound guidance was used in 77.7% patients, with stereotactic guidance utilized in the remaining 22.3% of patients. The results showed that in the 159 patients who had a representative image-guided biopsy, the false-negative rate was 18.7%. However, a less than 5% false-negative rate was observed in a subgroup analysis of 76 patients with a complete or partial clinical treatment response, and a residual imaging abnormality of two centimeters or smaller, and with at least six VAB samples. The study was published on October 7, 2020, in JAMA Surgery.

“Postneoadjuvant chemotherapy image-guided biopsy may identify pathologic complete response in the breast in selected patients,” concluded lead author Marios Konstantinos Tasoulis, PhD, of the Royal Marsden NHS Foundation Trust, and colleagues. “The technique can facilitate risk-adaptive surgery, and it can potentially even identify exceptional treatment responders for deescalation of local therapy.”

Adjuvant therapy involves any treatment given after primary therapy (such as surgery) to increase the chance of long-term survival; neoadjuvant therapy is treatment given before primary therapy.

Related Links:
Royal Marsden NHS Foundation Trust
University of Texas MD Anderson Cancer Center
Seoul National University Hospital


Pocket Fetal Doppler
CONTEC10C/CL
Ultrasound Table
Women’s Ultrasound EA Table
Medical Radiographic X-Ray Machine
TR30N HF
New
Half Apron
Demi

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.